Skip to content

NUVECTIS PHARMA, INC.

NVCT

CIK 0001875558

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$25.18M
−39.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.27
−18.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$25.13M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
26.53M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings